Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Capital Leases: 2012-2015

Historic Capital Leases for Arrowhead Pharmaceuticals (ARWR) over the last 4 years, with Sep 2015 value amounting to $540,792.

  • Arrowhead Pharmaceuticals' Capital Leases fell 36.38% to $378,862 in Q2 2016 from the same period last year, while for Jun 2016 it was $378,862, marking a year-over-year decrease of 36.38%. This contributed to the annual value of $540,792 for FY2015, which is 28.69% down from last year.
  • As of FY2015, Arrowhead Pharmaceuticals' Capital Leases stood at $540,792, which was down 28.69% from $758,340 recorded in FY2014.
  • Arrowhead Pharmaceuticals' 5-year Capital Leases high stood at $1.3 million for FY2012, and its period low was $540,792 during FY2015.
  • Its 3-year average for Capital Leases is $786,748, with a median of $758,340 in 2014.
  • Data for Arrowhead Pharmaceuticals' Capital Leases shows a maximum YoY decreased of 28.69% (in 2015) over the last 5 years.
  • Arrowhead Pharmaceuticals' Capital Leases (Yearly) stood at $1.3 million in 2012, then decreased by 17.26% to $1.1 million in 2013, then dropped by 28.53% to $758,340 in 2014, then decreased by 28.69% to $540,792 in 2015.